PLYX

PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that it has closed a private investment in public equity (“PIPE”) financing resulting in proceeds of $10 million. The PIPE financing closed on May 28, 2026.

Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner

PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), today announced its participation in the National Tay-Sachs & Allied Diseases Association (NTSAD) Annual Family Conference, taking place April 30 through May 3, 2026, at the Hyatt Regency in Reston, Virginia. “The NTSAD Annual Family Conference is an important opportunity to connect directly with the families and advocates at the heart of the rare disease community,” said Alex Yang, J.D.

PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II).

Company selected as a Diamond honoree for Excellence in Pediatric Care Company selected as a Diamond honoree for Excellence in Pediatric Care